Fed Circuit majority ‘problematically’ adds new rule in Actavis suit: chief judge

16-08-2019

The US Court of Appeals for the Federal Circuit yesterday, August 15, blocked Actavis’s attempt to market a generic version of Nalpropion Pharmaceuticals’ weight-loss drug Contrave (naltrexone hydrochloride and bupropion hydrochloride). 


US Court of Appeals for the Federal Circuit, Actavis, Nalpropion Pharmaceuticals, Contrave, weight-loss drugs, Circuit Judge Sharon Prost, generics, ANDA

LSIPR